Skandinaviska Enskilda Banken (SEB)
KZR

Skandinaviska Enskilda Banken (SEB)’s Kezar Life Sciences KZR Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,697
Closed -$260K – 911
2022
Q4 		$260K Sell
3,697
-214
-5% -$15.9K ﹤0.01% 772
2022
Q3 		$337K Hold
3,911
– – ﹤0.01% 783
2022
Q2 		$323K Hold
3,911
– – ﹤0.01% 853
2022
Q1 		$650K Buy
+3,911
New +$561K ﹤0.01% 807

Other funds holding KZR

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s KZR Position: Q1 2023 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Kezar Life Sciences (KZR) in Q1 2023, closing a stake of 3,697 shares — an estimated $260K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in KZR in Q1 2022 and held it in 4 quarters. The position peaked at $650K in Q1 2022. 136 funds tracked by Wall St. Rank hold KZR as of Q1 2023.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Kezar Life Sciences position as of Q1 2023 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 3,697 Kezar Life Sciences shares in Q1 2023, an estimated $260K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Kezar Life Sciences in Q1 2022 and held it in 4 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Kezar Life Sciences position peaked at $650K in Q1 2022.
  • 136 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2023.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2023, filed 11 May 2023.